| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
| Targets |
The primary target of Tricyclazole is the fungal melanin biosynthesis pathway. It inhibits the enzyme scytalone dehydratase, which is involved in the production of melanin. Melanin is essential for the formation of appressoria, which are infection structures that allow the fungus to penetrate the plant. By inhibiting melanin synthesis, tricyclazole prevents infection and reduces disease severity.
|
|---|---|
| ln Vitro |
In vitro, tricyclazole has been shown to inhibit melanin biosynthesis in fungal cultures. It inhibits the activity of scytalone dehydratase, leading to the accumulation of melanin precursors. The compound's antifungal activity has been confirmed in various in vitro models using Magnaporthe oryzae and other fungi.
|
| ln Vivo |
In vivo, tricyclazole is effective in controlling rice blast disease. It is used as a foliar spray or seed treatment in rice cultivation. The compound provides systemic protection against Magnaporthe oryzae, reducing the incidence and severity of rice blast.
|
| Enzyme Assay |
In vitro enzyme or receptor binding (non-cell) assays for tricyclazole involve measuring its inhibition of scytalone dehydratase activity. The assay uses a purified scytalone dehydratase enzyme and a substrate, such as scytalone. The production of melanin or its precursors is measured spectrophotometrically. The compound is incubated with the enzyme and substrate at varying concentrations, and the IC50 is determined.
|
| Cell Assay |
In vitro cell-based assays for tricyclazole are performed using fungal cultures of Magnaporthe oryzae. The fungus is grown in the presence of the compound, and melanin production is measured. The compound's effects on fungal growth, sporulation, and appressoria formation are assessed.
|
| Animal Protocol |
In vivo animal experiments for tricyclazole are conducted using plant models, specifically rice plants infected with Magnaporthe oryzae. The compound is applied as a foliar spray or seed treatment, and disease severity is assessed by measuring the number and size of lesions on the leaves. These studies confirm the compound's efficacy as a fungicide for rice blast control.
|
| ADME/Pharmacokinetics |
Pharmacokinetic (PK) properties of tricyclazole indicate that it is a systemic fungicide that is absorbed by plants. The compound has a molecular weight of 189.24 and a molecular formula of C9H7N3S. It is a solid at room temperature. It is metabolized in plants and has a relatively long residual activity. The compound is typically applied as a foliar spray or seed treatment.
|
| Toxicity/Toxicokinetics |
Toxicology (toxicology) data for tricyclazole indicate that it is of low toxicity to mammals. It is not highly toxic by ingestion or dermal exposure. The compound may cause mild skin and eye irritation. It should be handled with appropriate safety precautions. It is toxic to aquatic organisms and should be used with caution near water bodies.
|
| Additional Infomation |
Tricyclazole is a triazolobenzothiazole compound with the structure [1,2,4]triazolo[3,4-b][1,3]benzothiazole, where the 5-position is substituted with a methyl group. It is a fungicide used to control rice blast, but it has not been approved for use in the European Union. Tricyclazole also has anti-melanin synthesis and antifungal properties. It is the conjugate base of 5-methyl[1,2,4]triazolo[3,4-b][1,3]benzothiazole-1-onium.
Other information: Tricyclazole is a systemic fungicide used for the control of rice blast disease. It is also known as Beam. The compound inhibits melanin biosynthesis in Magnaporthe oryzae. Its CAS number is 41814-78-2. |
| Molecular Formula |
C9H7N3S
|
|---|---|
| Molecular Weight |
189.23
|
| Exact Mass |
189.036
|
| CAS # |
41814-78-2
|
| Related CAS # |
Tricyclazole-d3
|
| PubChem CID |
39040
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.5±0.1 g/cm3
|
| Melting Point |
187-188°C
|
| Index of Refraction |
1.806
|
| LogP |
2.28
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
13
|
| Complexity |
211
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CC1=C2C(=CC=C1)SC3=NN=CN23
|
| InChi Key |
DQJCHOQLCLEDLL-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C9H7N3S/c1-6-3-2-4-7-8(6)12-5-10-11-9(12)13-7/h2-5H,1H3
|
| Chemical Name |
8-methyl-[1,2,4]triazolo[3,4-b][1,3]benzothiazole
|
| Synonyms |
BIM; Beam; Tricyclazole
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~125 mg/mL (~660.54 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (10.99 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (10.99 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (10.99 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.2846 mL | 26.4229 mL | 52.8457 mL | |
| 5 mM | 1.0569 mL | 5.2846 mL | 10.5691 mL | |
| 10 mM | 0.5285 mL | 2.6423 mL | 5.2846 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
